SOSV

SOSV, established in 1995 and headquartered in Princeton, New Jersey, is a global venture capital firm specializing in early-stage investments. It focuses on deep tech innovations in the health and environmental sectors, supporting founders with breakthrough technologies through its HAX and IndieBio startup development programs. SOSV provides resources, facilities, and lab equipment to accelerate product development and scale, with a track record of helping its portfolio companies secure subsequent funding rounds led by top-tier investors.

Hugh Bowen

Associate

Weichang Ge

Analyst

Bradford Higgins

Venture Partner

Katie Hoffman

General Partner

Mohan Iyer

General Partner

Benjamin Joffe

Partner

Ji Ke

Partner

Stephen McCann

CFO and General Partner

Carthach McCarthy

CFO

Paul Monaghan

Principal

Brian Murphy

Finance Director

Eric Ramsay

Analyst

Sabriya Stukes Ph.D

Partner

Past deals in Medical

Prellis Biologics

Series C in 2025
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Afynia Laboratories

Seed Round in 2025
Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ria Health

Series B in 2025
Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Ostoform

Convertible Note in 2025
Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

Particella

Convertible Note in 2025
Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

RyboDyn

Pre Seed Round in 2025
RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Proton Intelligence

Seed Round in 2024
Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Serene Sleep

Seed Round in 2024
Serene Sleep is a medical technology company that focuses on improving sleep quality by addressing snoring and sleep apnea. It develops and offers a non-invasive, targeted treatment procedure using palatal implants, designed to reduce disruptive snoring and enhance overall sleep for both the individual and their partner.

Samphire Neuroscience

Seed Round in 2024
Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Macheon

Seed Round in 2024
Macheon AI is a robotics company specializing in the manufacture of surgical robots for head and neck procedures. These robots incorporate real-time, AI-driven decision support, aiming to enhance surgical precision, safety, and efficiency.

BioLattice

Seed Round in 2024
BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Vitarka Therapeutics

Seed Round in 2024
Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Machine Medicine

Convertible Note in 2024
Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement in patients, particularly those with Parkinson's disease. This platform delivers precise metrics, such as tremor and bradykinesia, from simple video clips, enabling secure, device-agnostic, and affordable patient data management.

Exosomm

Seed Round in 2024
Exosomm is an innovative foodtech start-up focused on developing nutritional solutions derived from natural milk exosomes. The company was founded based on research from Hadassah Medical Center, led by Prof. Reif's team. Exosomm's flagship product is a specialized food formula designed for patients suffering from inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. This product utilizes a patented active anti-inflammatory ingredient sourced from milk exosomes, which are isolated using a natural and environmentally friendly process. By targeting health and immunity, Exosomm aims to provide effective solutions for individuals with specific dietary needs.

Laguna Bio

Seed Round in 2024
Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

FREZENT

Seed Round in 2024
FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DisperseBio

Seed Round in 2024
DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Metabolic Psychiatry Labs

Seed Round in 2024
Metabolic Psychiatry Labs is a mental healthcare company that provides remote treatment solutions for mental illnesses. Their platform integrates metabolic and mental health research, data tracking, metabolic interventions, and personalized medical care, enabling patients to receive effective treatments from home. The company offers assessments, lab tests, and wellness solutions based on metabolic therapy.

Gatehouse Bio

Convertible Note in 2024
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Asta Bio

Seed Round in 2024
Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

Tinkeso Therapeutics

Seed Round in 2024
Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative cell therapies for treating cancer and autoimmune diseases. The company focuses on creating off-the-shelf, allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies. These therapies use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions, aiming to increase treatment accessibility and scalability.

heXem bio

Seed Round in 2024
heXem bio specializes in recording solutions for the early development of humans for longevity.

Zhenshi Medical

Convertible Note in 2024
Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

DeepSpin

Convertible Note in 2024
DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in developing artificial intelligence-powered magnetic resonance imaging (MRI) equipment. The company’s innovative technology aims to provide MRI imaging systems that are significantly smaller, lighter, and more cost-effective than traditional models. By leveraging generative topological design and deep learning techniques, DeepSpin's MRI machines enhance accessibility to medical imaging, making it available to a wider range of patients globally. This approach seeks to improve healthcare standards in various medical fields previously lacking adequate imaging solutions.

Afynia Laboratories

Seed Round in 2024
Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Flow Neuroscience

Convertible Note in 2024
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Valanx Biotech

Seed Round in 2024
Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

GlowDx

Convertible Note in 2024
GlowDx is a diagnostics company based in Midleton, Ireland, established in 2015. The company focuses on decentralizing molecular testing through innovative point-of-care technologies, which facilitate local access to diagnostics for tropical diseases. By combining novel molecular technology with effective delivery models, GlowDx aims to improve clinical outcomes while reducing the economic burden on patients and healthcare systems. This approach enhances the quality of life for individuals by ensuring they receive timely and accurate diagnostic information, thereby enabling healthcare providers to offer better-targeted treatments.

EIO Diagnostics

Convertible Note in 2024
EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.

HelEx

Convertible Note in 2024
Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Calder Biosciences

Seed Round in 2024
Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

Cell BioEngines

Pre Seed Round in 2024
Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

Cayuga Biotech

Convertible Note in 2024
Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Level Zero

Seed Round in 2024
Level Zero Health is a technology company specializing in advanced biosensor solutions. It develops wearable devices equipped with DNA-based sensors, designed to precisely monitor key endocrine biomarkers in real-time. By combining biochemistry and nanotechnology, the company collects novel data, empowering users to gain insights into their hormonal health.

DropGenie

Convertible Note in 2024
DropGenie is a biotechnology company founded in 2018 and based in Montreal, Canada. The company focuses on developing connected hardware that automates gene editing processes, thereby enhancing the efficiency of genetic engineering. Its platform streamlines liquid handling and experimental conditions, which helps scientists reduce costs while improving the standardization and reproducibility of their work. By generating standardized and compatible scientific information, DropGenie aims to accelerate the pace of discovery in the field of genetics, making advancements in gene editing more accessible to researchers.

Avisa Myko

Convertible Note in 2024
Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Samphire Neuroscience

Pre Seed Round in 2024
Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

XN Health

Convertible Note in 2024
XN Health is a medical device company based in Texas, founded in 2021. The company specializes in developing healthcare devices aimed at improving the process of mechanical ventilation. Its innovative technology focuses on phrenic nerve stimulation, which induces diaphragm contractions during ventilation. This approach helps protect against diaphragm dysfunction in patients who are mechanically ventilated, ultimately enabling them to wean off the ventilator more quickly and safely.

Chronus Health

Convertible Note in 2024
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Verdex Technologies

Convertible Note in 2023
Verdex Technologies Inc. is a company based in North Chesterfield, Virginia, that specializes in the design, patenting, and licensing of non-toxic nanofiber producing equipment for various applications, particularly in filtration and biomedical fields. The company leverages proprietary technology to mass produce advanced nanofibers, enabling the creation of high-quality nonwoven materials suitable for a wide range of uses, including engine filters, liquid filters, industrial air filters, and medical packaging. Verdex's innovative approach allows for the functionalization of nanofibers by incorporating nano-sized ingredients, enhancing the effectiveness of products like water filters. Committed to sustainability, Verdex utilizes biodegradable and bioresorbable polymers in its processes, ensuring that its production methods are environmentally friendly. Founded in 2011, the company aims to unlock the potential of nanofibers and improve quality of life through its advanced materials.

Lura Health

Seed Round in 2023
Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

RyboDyn

Seed Round in 2023
RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Prellis Biologics

Series C in 2023
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Valanx Biotech

Seed Round in 2023
Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

BioAesthetics

Convertible Note in 2023
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

FREZENT

Seed Round in 2023
FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio

Convertible Note in 2023
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Calder Biosciences

Seed Round in 2023
Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

LightHearted AI

Seed Round in 2023
LightHearted AI specializes in AI-driven remote cardiovascular diagnostics, offering a tool for swift, accurate, and cost-effective detection of heart conditions. Their medical device aims to prevent heart-related deaths by providing healthcare professionals with faster, more precise, and affordable support than existing technologies, thereby enhancing treatment procedures.

Cell BioEngines

Pre Seed Round in 2023
Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

Avisa Myko

Seed Round in 2023
Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Verdex Technologies

Convertible Note in 2023
Verdex Technologies Inc. is a company based in North Chesterfield, Virginia, that specializes in the design, patenting, and licensing of non-toxic nanofiber producing equipment for various applications, particularly in filtration and biomedical fields. The company leverages proprietary technology to mass produce advanced nanofibers, enabling the creation of high-quality nonwoven materials suitable for a wide range of uses, including engine filters, liquid filters, industrial air filters, and medical packaging. Verdex's innovative approach allows for the functionalization of nanofibers by incorporating nano-sized ingredients, enhancing the effectiveness of products like water filters. Committed to sustainability, Verdex utilizes biodegradable and bioresorbable polymers in its processes, ensuring that its production methods are environmentally friendly. Founded in 2011, the company aims to unlock the potential of nanofibers and improve quality of life through its advanced materials.

Valanx Biotech

Seed Round in 2023
Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

TippingPoint Biosciences

Seed Round in 2023
TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

Karma Biotechnologies

Seed Round in 2023
Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.

Samphire Neuroscience

Convertible Note in 2023
Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Pannex Therapeutics

Seed Round in 2023
Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Diadem Biotherapeutics

Convertible Note in 2023
Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Pear Bio

Series A in 2023
Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Care Constitution

Seed Round in 2023
Care Constitution is a telehealth service that provides a platform for clients to access health checkups online. The company focuses on improving healthcare delivery by assisting doctors with diagnostic testing through the use of artificial intelligence technology. This innovative approach aims to set a standard of care in medicine by offering objective, reproducible, and quantitative healthcare assessments. By enhancing the accuracy of diagnoses, Care Constitution seeks to support healthcare professionals in delivering better patient outcomes.

Stämm Biotech

Series B in 2023
Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Vitarka Therapeutics

Seed Round in 2023
Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

AuraSense

Pre Seed Round in 2023
AuraSense is focused on enhancing neurological assessments through the integration of artificial intelligence and automation. The company has developed a digital touch technology that enables the detection of early signs of limb damage, facilitating remote physical examinations for various diseases. By combining elements of video game technology with practical medical procedures, AuraSense provides neurologists with a data-driven and quantifiable approach to evaluate patients' cognitive and physical health. This innovation allows for accurate performance assessments, leading to personalized treatment plans tailored to individual patient needs, ultimately aiming to improve health outcomes.

Cayuga Biotech

Seed Round in 2023
Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

DNALite Therapeutics

Convertible Note in 2023
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Particella

Convertible Note in 2023
Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Kolibri

Convertible Note in 2023
Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Cell BioEngines

Pre Seed Round in 2023
Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

Renegade.bio

Series A in 2023
Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Pear Bio

Convertible Note in 2023
Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Moirai Biodesign

Seed Round in 2023
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

R-Zero

Series C in 2023
R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

BiomeSense

Seed Round in 2023
BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Renegade.bio

Convertible Note in 2023
Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Midoconline

Convertible Note in 2023
Midoconline is a technology company that specializes in providing medical and wellness services aimed at enhancing quality of life. The company has developed a telehealth platform that facilitates video-based consultations between patients and doctors. Through a mobile application, patients can easily connect with healthcare professionals to receive remote consultations for non-emergency medical issues, thereby improving access to healthcare services.

QV Bioelectronics

Seed Round in 2023
QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Metabolomic Diagnostics

Seed Round in 2022
Metabolomic Diagnostics Ltd., established in 2011 and based in Little Island, Ireland, is a medical diagnostics company focused on early disease detection. It specializes in developing a mass spectrometry-based diagnostic platform that analyzes multiple biomarkers simultaneously, enabling predictive diagnosis of complex diseases. The company's primary application is a blood test for predicting the risk of pre-eclampsia, a pregnancy complication characterized by high blood pressure and protein in the urine, which can lead to restricted blood supply to the fetus. By identifying diagnostic biomarker panels and translating them into clinical assays, Metabolomic Diagnostics aims to improve pregnancy outcomes through early intervention.

Aluna

Series B in 2022
Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

BioROSA Technologies

Convertible Note in 2022
BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Bisu

Seed Round in 2022
Bisu is a health technology company that offers a home health lab designed to enhance personal well-being through urine and saliva tests. Its devices monitor various health metrics, including dietary health, fat metabolism, and hydration levels, providing users with daily feedback on electrolytes, hydration, pH, ketones, and uric acid via a mobile application. This functionality enables individuals to track burned body fat, maintain metabolic health, achieve optimal ketosis, and improve physical endurance. Bisu has received recognition for its innovation, having been awarded by prestigious organizations such as Johnson & Johnson Innovation and MedTech Innovator, and it gained further acclaim at CES 2020 with the IHS Markit Innovation Award.

Free to Feed

Seed Round in 2022
Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

HelEx

Seed Round in 2022
Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Vitarka Therapeutics

Seed Round in 2022
Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

ChektAhora

Seed Round in 2022
ChektAhora specializes in providing at-home testing kits for sexually transmitted infections (STIs) and other contagious diseases, including respiratory viruses like influenza and COVID-19. The company offers a technology-enabled platform that allows customers to access confidential and convenient health tests without the discomfort of traditional testing methods. By utilizing advanced testing techniques such as PCR, antigens, and antibodies, ChektAhora aims to deliver laboratory-quality results directly to individuals in Latin America, ensuring a pain-free experience.

Gatehouse Bio

Seed Round in 2022
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Verdex Technologies

Series A in 2022
Verdex Technologies Inc. is a company based in North Chesterfield, Virginia, that specializes in the design, patenting, and licensing of non-toxic nanofiber producing equipment for various applications, particularly in filtration and biomedical fields. The company leverages proprietary technology to mass produce advanced nanofibers, enabling the creation of high-quality nonwoven materials suitable for a wide range of uses, including engine filters, liquid filters, industrial air filters, and medical packaging. Verdex's innovative approach allows for the functionalization of nanofibers by incorporating nano-sized ingredients, enhancing the effectiveness of products like water filters. Committed to sustainability, Verdex utilizes biodegradable and bioresorbable polymers in its processes, ensuring that its production methods are environmentally friendly. Founded in 2011, the company aims to unlock the potential of nanofibers and improve quality of life through its advanced materials.

Intrinsic Medicine

Convertible Note in 2022
Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Proton Intelligence

Seed Round in 2022
Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Laguna Bio

Seed Round in 2022
Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

RxDiet

Seed Round in 2022
RxDiet is a developer of a nutritional guidance platform that leverages artificial intelligence and automation to provide personalized meal solutions and health interventions. The company partners with national food retailers and leading health plans to deliver fresh groceries tailored to individual cultural and lifestyle preferences. This approach not only promotes a balanced diet but also aims to achieve exceptional clinical outcomes and cost savings for users. By integrating "food as medicine" principles, RxDiet addresses the growing demand for effective nutritional support in healthcare.

Melio

Seed Round in 2022
Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Samphire Neuroscience

Seed Round in 2022
Samphire Neuroscience is a neurotechnology company based in London, England, founded in 2021. The company focuses on women's health and lifestyle enhancement through innovative solutions. Its primary product is a headband device that employs non-invasive electrical neuromodulation to stimulate specific areas of the brain. This technology aims to alleviate symptoms commonly associated with menstrual cycles, including pain, fatigue, and mood disturbances, thereby improving the overall well-being of women.

Machine Medicine

Seed Round in 2022
Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement in patients, particularly those with Parkinson's disease. This platform delivers precise metrics, such as tremor and bradykinesia, from simple video clips, enabling secure, device-agnostic, and affordable patient data management.

Prellis Biologics

Series C in 2022
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Chronos DX

Seed Round in 2022
ChronosDx is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics. The firm focuses on creating bioassay technology tailored for diagnostics, drug screening, and development. ChronosDx develops high-performance, cost-effective, and scalable technology that effectively detects various biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This innovative platform enables medical professionals to monitor biomarkers both in-line and in vivo, enhancing the capabilities of healthcare diagnostics.

GlowDx

Seed Round in 2022
GlowDx is a diagnostics company based in Midleton, Ireland, established in 2015. The company focuses on decentralizing molecular testing through innovative point-of-care technologies, which facilitate local access to diagnostics for tropical diseases. By combining novel molecular technology with effective delivery models, GlowDx aims to improve clinical outcomes while reducing the economic burden on patients and healthcare systems. This approach enhances the quality of life for individuals by ensuring they receive timely and accurate diagnostic information, thereby enabling healthcare providers to offer better-targeted treatments.

SyntheX

Convertible Note in 2022
SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Moirai Biodesign

Convertible Note in 2022
Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016 and based in Barcelona, Spain, the company specializes in creating non-invasive tests for the in-situ diagnosis of various cancers using patients' blood. It also develops in-vivo diagnosis systems that assist in surgical procedures and monitor patient conditions, alongside therapeutical drugs aimed at treating cancer. Moirai Biodesign's innovative pipeline includes RNA biomarker discovery, the design of plug-and-play bio devices, and advanced platform delivery systems, all aimed at improving early cancer detection and targeted treatment options.

Briefcase Biotec

Convertible Note in 2022
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

EIO Diagnostics

Convertible Note in 2022
EIO Diagnostics Inc. is a Canadian company specializing in mastitis detection systems for dairy cattle. Founded in 2017 and based in Duncan, the company has developed the FirstLook Mastitis system, which employs a multispectral sensor to capture images of the udder as cows enter the milk parlor. This technology utilizes infrared image analysis and computer vision to automate the detection of early indicators of mastitis, allowing farmers to prevent infections before they occur. By installing a single sensor at the entry of the rotary milking system, EIO Diagnostics enables farmers to monitor udder health efficiently, thereby enhancing livestock health and improving milk quality while reducing labor and associated costs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.